Application in moderate to severe hidradenitis suppurativa based on results from two Phase 3 studies where bimekizumab-bkzx showed clinically meaningful improvements vs. placebo at Week 16 which were sustained to Week 48Application for the additional bimekizumab-bkzx 2mL device presentations aims to provide more opt.
FDA Accepts Supplemental Biologics License Applications for BIMZELX[®] for Moderate to Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations .